The PediCAP trial (ISRCTN63115131) enrolled 1,101 children across 13 hospitals in five African countries and found that switching clinically improving children from injectable antibiotics to oral therapy is safe and effective. Readmission and 28-day death rates were similar across groups (6% oral amoxicillin, 7% amoxicillin-clavulanate, 6% injectable). Children who switched to oral drugs were discharged about one day earlier, and four- to five-day antibiotic courses worked as well as seven- to eight-day regimens. The study was funded by the EU's EDCTP2 programme and sponsored by the Penta Foundation.
Large Trial Finds Early Switch From Injectables To Oral Antibiotics Safe For Children With Severe Pneumonia
By switching to oral antibiotics
A major international clinical trial has shown that children hospitalised with severe community-acquired pneumonia can be safely switched from injectable antibiotics to oral therapy once they begin to improve, allowing many to complete treatment at home.
Study design and scope
The PediCAP trial (ISRCTN63115131) enrolled 1,101 children aged 2 months to 6 years across 13 hospitals in South Africa, Uganda, Zambia, Zimbabwe and Mozambique. The study was led by researchers at St George's, University of London and the UCL Innovative Clinical Trials Unit with clinical partners across Africa and Europe.
How the trial worked
All children began treatment with an injectable antibiotic. Once clinically improved, participants were randomly assigned either to switch to oral amoxicillin, to switch to oral amoxicillin-clavulanate, or to continue injectable therapy for the full five days. Investigators compared recovery, 28-day readmission or death, length of hospital stay and different treatment durations.
Key findings
- Recovery rates were comparable whether children switched early to oral antibiotics or continued injectable therapy.
- Rates of hospital readmission or death within 28 days were similar across groups: 6% for oral amoxicillin, 7% for oral amoxicillin-clavulanate and 6% for full-course injectable therapy.
- Children who switched to oral antibiotics were discharged roughly one day earlier on average than those who completed five days of injectable treatment in hospital.
- Four- to five-day antibiotic courses were as effective as longer seven- to eight-day regimens.
"Every year millions of children around the world are admitted to hospital with severe pneumonia. Our study shows that once a child is clinically improving, it is safe to switch from injectable to oral antibiotics, and complete treatment at home," said Professor Julia Bielicki, Professor of Paediatric Infectious Diseases at St George's, University of London.
Implications
The findings support revising inpatient care pathways to allow an earlier switch to oral antibiotics for clinically improving children. This could reduce hospital stays, lower costs and free up beds in resource-limited settings, while also contributing to better antibiotic stewardship. However, decisions should follow clinical judgment and local guidelines, and the trial results apply to children who show clear clinical improvement after initial injectable therapy.
Funding and context
The trial was funded by the European Union's EDCTP2 programme and sponsored by the Penta Foundation. The results arrive amid growing global concern about antibiotic resistance: the World Health Organization estimates large future costs associated with treating resistant infections if current trends continue.
Help us improve.
